Danish biotech company Zealand Pharma’s pipeline contains several research projects including a phase I obesity candidate that, in the preclinical version, proved more effective than one of Novo’s drugs. Zealand is also turning to another Danish company’s preserves.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.